Literature DB >> 11834505

Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle.

Chikaya Omichi1, Shengmei Zhou, Moon-Hyoung Lee, Ajay Naik, Che-Ming Chang, Alan Garfinkel, James N Weiss, Shien-Fong Lin, Hrayr S Karagueuzian, Peng-Sheng Chen.   

Abstract

The effects of acute amiodarone infusion on dynamics of ventricular fibrillation (VF) are unclear. Six isolated swine right ventricles (RVs) were studied in vitro. Activation patterns during VF were mapped optically, whereas action potentials were recorded with a glass microelectrode. At baseline, VF was associated with frequent spontaneous wave breaks. Amiodarone (2.5 microg/ml) reduced spontaneous wave breaks and increased the cycle length (CL) of VF from 83.3 +/- 17.8 ms at baseline to 118.4 +/- 25.8 ms during infusion (P < 0.05). Amiodarone increased the reentrant wave front CL (114.4 +/- 15.5 vs. 78.2 +/- 19.0 ms, P < 0.05) and central core area (4.1 +/- 3.8 vs. 0.9 +/- 0.3 mm2, P < 0.05). Within 30 min of infusion, VF terminated (n = 1), converted to ventricular tachycardia (VT) (n = 1) or continued at a slower rate (n = 4). Amiodarone flattened the APD restitution curves. We conclude that amiodarone reduced spontaneous wave breaks. It might terminate VF or convert VF to VT. These effects were associated with the flattening of APD restitution slope and increased core size of reentrant wave fronts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834505     DOI: 10.1152/ajpheart.00633.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  8 in total

1.  Acute amiodarone promotes drift and early termination of spiral wave re-entry.

Authors:  Harumichi Nakagawa; Haruo Honjo; Yuko S Ishiguro; Masatoshi Yamazaki; Yusuke Okuno; Masahide Harada; Hiroki Takanari; Ichiro Sakuma; Kaichiro Kamiya; Itsuo Kodama
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

2.  The impact of catecholamines in patients with or without beta-blockers on the ventricular fibrillation cycle length and ventricular fibrillation cycle length variability.

Authors:  Bokyung Min; Jeffrey Kluger; James S Kalus; Danette Guertin; Brian F McBride; C Michael White
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-07       Impact factor: 1.468

3.  Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.

Authors:  Ian N Sabir; Lucia M Li; Victoria J Jones; Catharine A Goddard; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2007-09-06       Impact factor: 3.657

Review 4.  The role of action potential alternans in the initiation of atrial fibrillation in humans: a review and future directions.

Authors:  Michael R Franz; Sameer M Jamal; Sanjiv M Narayan
Journal:  Europace       Date:  2012-11       Impact factor: 5.214

5.  The effects of atrial ganglionated plexi stimulation on ventricular electrophysiology in a normal canine heart.

Authors:  Bo He; Zhibing Lu; Wenbo He; Bing Huang; Lilei Yu; Liu Wu; Bo Cui; Xiaorong Hu; Hong Jiang
Journal:  J Interv Card Electrophysiol       Date:  2013-02-08       Impact factor: 1.900

6.  Restitution analysis of alternans and its relationship to arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts.

Authors:  Ian N Sabir; Lucia M Li; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2007-08-18       Impact factor: 3.657

7.  Phase Relationship between Alternans of Early and Late Phases of Ventricular Action Potentials.

Authors:  Linyuan Jing; Anuj Agarwal; Sonam Chourasia; Abhijit Patwardhan
Journal:  Front Physiol       Date:  2012-06-08       Impact factor: 4.566

8.  Amiodarone inhibits apamin-sensitive potassium currents.

Authors:  Isik Turker; Chih-Chieh Yu; Po-Cheng Chang; Zhenhui Chen; Yoshiro Sohma; Shien-Fong Lin; Peng-Sheng Chen; Tomohiko Ai
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.